Climb Bio Inc (CLYM) Cash Flow Statement
Climb Bio Inc (CLYM) generated -$52.7M of operating cash flow over the twelve months to 2026-06-30, spent $1.8M on capital expenditure and had free cash flow of -$54.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLYMClimb Bio IncFollow CLYM — free
—
Price chart with a free account
- Market cap
- 585.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -36.1 | -37.4 | -20.6 | -15.6 | -54.4 | -52.7 | |
| Capital expenditure | — | — | — | 5.0 | 0.2 | -1.8 | |
| Free cash flow | — | — | — | -20.6 | -54.5 | -54.5 | |
| Stock-based compensation | 3.7 | 7.0 | 12.8 | 5.6 | 8.1 | — |
USD millions · SEC XBRL
Climb Bio Inc — questions
- What is Climb Bio Inc's operating cash flow?
- -$52.7M over the twelve months to 2026-06-30.
- How much does Climb Bio Inc spend on capital expenditure?
- $1.8M over the twelve months to 2026-06-30.
- What is Climb Bio Inc's free cash flow?
- -$54.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Climb Bio Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.